Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. - Wikidata - awgldk - TriplyDB

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

http://www.wikidata.org/entity/Q34409966

about

Budesonide for induction of remission in Crohn's disease Budesonide for maintenance of remission in Crohn's disease Budesonide for maintenance of remission in Crohn's disease Budesonide for induction of remission in Crohn's disease New steroids and new salicylates in inflammatory bowel disease: a critical appraisal Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease Oral budesonide in the management of Crohn's disease.Anti-TNF antibody treatment of Crohn's disease.Management of Crohn's disease.Budesonide in the treatment of inflammatory bowel disease.Review article: the limitations of corticosteroid therapy in Crohn's disease.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.The effectiveness of budesonide therapy for Crohn's disease.Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group Managing refractory Crohn's disease: challenges and solutions Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients.Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.Management of ulcerative colitis and Crohn's disease.How to read a clinical trial paper: a lesson in basic trial statistics.Methods to avoid infections in patients with inflammatory bowel disease.State of the art: IBD therapy and clinical trials in IBD.Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation.Maintenance of medically induced remission of Crohn's disease.Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.Budesonide Use and Hospitalization Rate in Crohn's Disease: Results From a Cohort at a Tertiary Care IBD Referral Center.Budesonide for Crohn's disease.Cost effectiveness of treatments for inflammatory bowel disease.Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Oral locally active steroids in inflammatory bowel disease.The role of Budesonide-MMX in active ulcerative colitis.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?New treatments for inflammatory bowel disease.Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.Practical guidelines for the treatment of inflammatory bowel disease.The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.

P2860

Q24187309-CB3F3FCF-5A73-4E12-84D6-090AE2EDA9C8 Q24194313-D05B036A-DBD4-49B1-B0EB-BC968BBD7ED1 Q24241252-6BBE5348-B6F6-462D-88F0-6587414B204C Q24242729-5E5F80F0-4849-4AAD-9493-F7EE76A7D8D1 Q28192793-E6900CB0-5C4F-413D-B7D6-B3863A840922 Q28345937-4628EA3C-7D7E-4E25-AD24-7F70C9426BF3 Q30311870-EEA9DF57-904C-4360-BF70-08CC1717013E Q33782391-E7F67F5E-E58B-4434-B361-9DB08EF6ED81 Q33785519-F6B96163-2C8C-4491-B614-D9DA958399A3 Q34203594-8CB91F2A-0DCE-4687-ABEB-4E540BDE79AC Q34374135-89F0B69C-9BEB-47E9-AFB2-6D61502FC004 Q34564902-A380DF52-08FD-4FA4-A1F0-4B58242A1267 Q34786715-D7539A26-D8DA-415A-9E40-58286595DFD6 Q35350179-DA3A61F3-82E0-4702-AE40-A84A0BECF1BD Q35460367-34B76FEA-AF68-41FB-91CC-02809130AFCB Q35596422-B6BCCD3B-4B52-4A9A-A9E3-32AE4730F427 Q35599763-E79188BD-8D08-46E4-B4BB-648797362691 Q36004867-3CA69825-2140-4F33-B266-D15937D23AB6 Q36049663-C81B4751-99FA-4266-866F-D2497E671E3B Q36171733-6C05828D-51C7-4D74-837A-5D1F873E4705 Q36299319-B1FD49BE-134B-44E3-8446-B6595F2FA754 Q36659176-F4809BB9-0188-4A20-92D5-3FAF2B342955 Q36964735-6C4D110E-EEA9-4821-A649-97CC35CA8B61 Q37073410-45E19F97-1A48-482F-BFB8-71492252A1FE Q37142095-B2A43014-C600-4DC8-BB18-F92484D2D304 Q37180423-C67AA821-D9D9-48F3-8C94-4E0A101E8818 Q37233955-FF3888EF-71E4-4A66-A5EF-9B8528384B87 Q37554383-6D497807-51BB-4608-A355-7974B782E2A3 Q37832729-3F58A39D-9739-4A9A-BD08-63A3E64DFAAB Q37853356-F3032C67-008A-4E8D-B696-9A50055E7578 Q37862584-8A07EBB4-D6DB-4D7E-9CC2-ADEE467DC1C0 Q38025531-2E2C2B37-2587-400A-8025-8F399DF39F12 Q38185703-EB776A55-EC4E-401B-A523-44066E1B49BE Q38196945-777F7983-E93C-4313-81CC-A5A01BD9BFBA Q38216510-1A01C69A-2168-44D0-B219-98AD06FF593A Q38634215-0CA20219-4047-4F5D-932C-F948A2426F2E Q38726458-BF4FAE5D-30B6-4FA0-AA56-AC8A3DEF385F Q40156835-61600E23-700A-429F-A796-2A7B07919C6D Q42846582-211D8366-138F-4B34-9759-DA5D88385CDD Q42982038-BC3B856C-B8DE-45E7-AE78-B472C0D9997C

P2860

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

http://www.wikidata.org/entity/Q34409966

description

1996 nî lūn-bûn

@nan

1996 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

name

Budesonide prolongs time to re ...... ebo controlled one year study.

@ast

Budesonide prolongs time to re ...... ebo controlled one year study.

@en

Budesonide prolongs time to re ...... ebo controlled one year study.

@nl

type

label

Budesonide prolongs time to re ...... ebo controlled one year study.

@ast

Budesonide prolongs time to re ...... ebo controlled one year study.

@en

Budesonide prolongs time to re ...... ebo controlled one year study.

@nl

prefLabel

Budesonide prolongs time to re ...... ebo controlled one year study.

@ast

Budesonide prolongs time to re ...... ebo controlled one year study.

@en

Budesonide prolongs time to re ...... ebo controlled one year study.

@nl

P1433

Q34409966-8C18063D-84D2-4502-B4E2-52D03D7BD9EF

P1476

Q34409966-E3FABA20-912D-42F2-BA7F-554EB66AFEE7

P2093

Q34409966-13EFE328-4E3B-4353-BBBB-1E7B6292E85E

Q34409966-290A4C84-F329-4853-BE98-4983C66EE4F3

Q34409966-2BF33155-1652-4615-8BA2-71C773D4BFC6

Q34409966-384E3B7D-305D-4677-B037-0439DD1B867A

Q34409966-4BEE4283-2044-4341-94A1-AB9B49638CCC

Q34409966-52E65D86-A3FB-4FA0-BA2A-E0D2EEF2D010

Q34409966-81D13C6F-811C-44A9-A05B-798A1EF33518

Q34409966-9366F357-01D8-45EB-BD49-05D7EB210970

Q34409966-AFD8BB6C-4CE7-4EB1-900E-D3B8B0992547

Q34409966-B78306C0-80EE-4C9D-A0A0-3B3F2763941B

P2860

Q34409966-B34B8EB4-9EE1-453D-950A-BA4BC999C983

Q34409966-B7A680F9-BB15-4C1C-9B8C-181325DB2C89

Q34409966-C9CE67D3-0532-4C5F-B543-A1768A173132

Q34409966-D83BF9AD-045A-4AD0-AA10-FBD7190F6247

P304

Q34409966-CF9C5384-C861-4BB3-9B56-8FE4BD758C95

P31

Q34409966-F96C4F54-8BCB-411D-A9AE-3ED031099C91

P356

Q34409966-41BB2A11-39DA-4064-A547-23D5EE7D192F

P407

Q34409966-1E5AC0C6-EA73-4E65-82CA-B3EB72DC0D96

P433

Q34409966-16F8CB3A-A818-47DC-A831-7775D807CE43

P478

Q34409966-B9AC5C7D-55C7-4E39-962A-FA02428E10BB

P577

Q34409966-781841FD-043A-4D3E-B074-98AA3CB29BA9

P5875

Q34409966-F990B14F-D250-494C-97F3-99134AFCC1CF

P698

Q34409966-A05FF773-91DD-4E7C-A385-6DEB8BC916C8

P921

Q34409966-060836EA-BE61-4333-95F2-600DBF248EE0

Q34409966-AF97BD0A-3AC4-4F81-827F-F4DD5B05F993

P932

Q34409966-5C56E73D-41F1-4D77-A564-8FCE55B1FE8F

P356

P1433

P1476

Budesonide prolongs time to re ...... ebo controlled one year study.

@en

P2093

Danielsson A

http://www.w3.org/2001/XMLSchema#string

Goebell H

http://www.w3.org/2001/XMLSchema#string

Hodgson H

http://www.w3.org/2001/XMLSchema#string

Jewell D

http://www.w3.org/2001/XMLSchema#string

Lamers C

http://www.w3.org/2001/XMLSchema#string

Lorenz-Meyer H

http://www.w3.org/2001/XMLSchema#string

Löfberg R

http://www.w3.org/2001/XMLSchema#string

Malchow H

http://www.w3.org/2001/XMLSchema#string

Olaison G

http://www.w3.org/2001/XMLSchema#string

Ostergaard Thomsen O

http://www.w3.org/2001/XMLSchema#string

P2860

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

Frequency of glucocorticoid resistance and dependency in Crohn's disease

National Cooperative Crohn's Disease Study: results of drug treatment.

Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty.

P304

82-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.39.1.82

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

1996-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14324720

http://www.w3.org/2001/XMLSchema#string

P698

8881815

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

1383237

http://www.w3.org/2001/XMLSchema#string